APLS earnings: a negative outcome, -10.1%

On May 7, 2024, Apellis Pharmaceuticals, Inc. reached its earnings. The result was a negative outcome, and the stock moved -10.1% in the window around the event. It had already run -15.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.